Inventor · disambiguated record
Stewart Shuman
Also filed as: SHUMAN STEWART
31 granted patents·9 pending applications·416 citations·filing 1994–2025
97Inventor score
Files withMEMORIAL SLOAN KETTERING CANCER CENTER19SLOAN KETTERING INST CANCER9LIFE TECHNOLOGIES CORP3SHUMAN STEWART3CHESNUT JONATHAN D1
Top patents by PatentIndex Score
40 records- 0196US10736962B2Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2017·Granted Aug 11, 2020·15 cites·22 claims
- 0296US6916632B2Methods and reagents for molecular cloningSLOAN KETTERING INST CANCER·Filed 2001·Granted Jul 12, 2005·63 cites·36 claims
- 0396US5766891AMethod for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomeraseSLOAN KETTERING INST CANCER·Filed 1994·Granted Jun 16, 1998·170 cites·11 claims
- 0495US12036279B2Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2022·Granted Jul 16, 2024·2 cites·8 claims
- 0595US11986503B2Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2022·Granted May 21, 2024·2 cites·14 claims
- 0694US11285209B2Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Mar 29, 2022·3 cites·10 claims
- 0794US11253560B2Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Feb 22, 2022·3 cites·19 claims
- 0894US10639366B2Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2016·Granted May 5, 2020·10 cites·16 claims
- 0994US10548930B2Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2016·Granted Feb 4, 2020·15 cites·18 claims
- 1093US11541087B2Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Jan 3, 2023·2 cites·12 claims
- 1193US10512662B2Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2017·Granted Dec 24, 2019·6 cites·20 claims
- 1291US7550295B2Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomeraseSLOAN KETTERING INST CANCER·Filed 2006·Granted Jun 23, 2009·5 cites·7 claims
- 1391US7026141B2Topoisomerase-based reagents and methods for molecular cloningSLOAN KETTERING INST CANCER·Filed 2003·Granted Apr 11, 2006·15 cites·23 claims
- 1487US10765711B2Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2019·Granted Sep 8, 2020·2 cites·19 claims
- 1586US7528241B2Methods and reagents for molecular cloningLIFE TECHNOLOGIES CORP·Filed 2005·Granted May 5, 2009·4 cites·10 claims
- 1684US2025177518A1Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2024·Application pending·0 cites
- 1782US6548277B1Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomeraseSLOAN KETTERING INST CANCER·Filed 1997·Granted Apr 15, 2003·37 cites·9 claims
- 1879US12397029B2Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2022·Granted Aug 26, 2025·0 cites·13 claims
- 1975US11884939B2Vaccinia virus mutants useful for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2021·Granted Jan 30, 2024·0 cites·16 claims
- 2071US8192932B2Covalent joining of DNA strands to RNA strands catalyzed by vaccinia topoisomeraseSHUMAN STEWART·Filed 2010·Granted Jun 5, 2012·2 cites·19 claims
- 2170US12252702B2Recombinant poxviruses for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2019·Granted Mar 18, 2025·0 cites·24 claims
- 2270US2009328244A1Methods and reagents for molecular cloningLIFE TECHNOLOGIES CORP·Filed 2009·Application pending·0 cites
- 2369US7662556B2Covalent joining of DNA to RNA by vaccinia topoisomerase and uses thereofSLOAN KETTERING INST CANCER·Filed 2003·Granted Feb 16, 2010·3 cites·20 claims
- 2469US6653106B1Topoisomerase-based ligation and cloning methodsSLOAN KETTERING INST CANCER·Filed 1998·Granted Nov 25, 2003·23 cites·17 claims
- 2569US6420163B1Pharmacological targeting of mRNA cap formationFiled 2000·Granted Jul 16, 2002·1 cites·14 claims
- 2669US6232070B1Pharmacological targeting of mRNA cap formationFiled 1999·Granted May 15, 2001·25 cites·21 claims
- 2769US2015093788A1Methods and reagents for molecular cloningLIFE TECHNOLOGIES CORP·Filed 2014·Application pending·0 cites
- 2865US11242509B2Vaccinia virus mutants useful for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2018·Granted Feb 8, 2022·0 cites·20 claims
- 2964US8551739B2Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomeraseSHUMAN STEWART·Filed 2007·Granted Oct 8, 2013·0 cites·9 claims
- 3063US11426460B2Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Aug 30, 2022·0 cites·20 claims
- 3162US6787341B2Pharmacological targeting of bacterial DNA ligase for treatment and prevention of bacterial infectionsSLOAN KETTERING INST CANCER·Filed 2002·Granted Sep 7, 2004·1 cites·2 claims
- 3262US2025179524A1Recombinant poxviruses for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2025·Application pending·0 cites
- 3360US2012129225A1Methods and reagents for molecular cloningCHESNUT JONATHAN D·Filed 2011·Application pending·0 cites
- 3452US2021023151A1Oncolytic vaccinia virus expressing immune checkpoint blockade for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2019·Application pending·0 cites
- 3552US2006134642A1Pharmacological targeting of bacterial DNA ligase for treatment and prevention of bacterial infectionsSLOAN KETTERING INST CANCER·Filed 2004·Application pending·0 cites
- 3651US2021177964A1Heat-inactivated vaccinia virus as a vaccine immune adjuvantMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2018·Application pending·0 cites
- 3750US2012322109A1Covalent Joining of DNA Strands to RNA Strands Catalyzed by Vaccinia TopoisomeraseSHUMAN STEWART·Filed 2012·Application pending·0 cites
- 3849US6451583B1Pharmacological targeting of mRNA cap formation for treatment of parasitic infectionsFiled 2000·Granted Sep 17, 2002·1 cites·4 claims
- 3947US6107040APharmacological targeting of mRNA cap formationFiled 1998·Granted Aug 22, 2000·6 cites·20 claims
- 4041US6844167B2Pharmacological targeting of mRNA cap formation for treatment of parasitic infectionsFiled 2002·Granted Jan 18, 2005·0 cites·7 claims
Join the waitlist — get patent alerts
Get an alert when Stewart Shuman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →